Microarray-Tumor Reveal® FFPE
Also known as: aCGH, CGH, CMA, Microarray Oncology, Reveal® SNP Array
Use
This test will detect chromosomal imbalance that may be present in neoplastic disorders and clonal evolution. It provides detection of copy-neutral loss of heterozygosity of any chromosome, and the percent and location of homozygosity, that may be associated with cancer gene mutations.
Special Instructions
Not provided.
Limitations
This SNP assay does not detect balanced rearrangements, low-level mosaicism (<10%), marker chromosomes containing only heterochromatin, or tetraploidy. Additionally, some formalin-fixed tissue genotypes cannot be determined, limiting the ability to detect genomic dosage. Truly balanced chromosomal alterations will not be detected, and the test's capability to detect mosaicism is variable depending on the segment size. Empirical studies have noted that whole chromosome 22 mosaicism under 10.0% may not be detected.
Methodology
Microarray
Biomarkers
Unknown CNV
Copy Number Region
LOINC Codes
- 31208-2 - Specimen source
- 48000-4 - Chromosome Bld/T
- 62365-2 - Diagnostic imp Spec-Imp
- 48672-0 - Clinical cytogeneticist Spec
- 11502-2 - Laboratory report
Result Turnaround Time
12-15 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
One paraffin block or ten 10-micron thick section slides
Minimum Volume
Ten 10-micron thick section slides
Container
Paraffin block transport pouch
Collection Instructions
FFPE specimen should be fixed in 10% neutral-buffered formalin or formaldehyde. Improperly embedded preparations and decalcified bone or bone core cannot be processed.
Storage Instructions
Room temperature
Causes for Rejection
Upon receipt, suitability of the specimen will be determined by the Cytogenetics laboratory.
Other tests from different labs that may be relevant